| Pomi-T — A proprietary, oral, polyphenol-rich botanical supplement combining pomegranate (Punica granatum), broccoli (Brassica oleracea), turmeric (Curcuma longa), and green tea (Camellia sinensis). Formally classified as a multi-ingredient botanical food supplement rather than an isolated compound or approved anticancer drug, Pomi-T is designed to deliver complementary phytochemicals including ellagitannins, catechins, glucosinolates, isothiocyanones, and curcuminoids. Its principal clinical application investigated to date is modulation of prostate-specific antigen (PSA) progression in men with localized prostate cancer under surveillance or following previous treatment. Its anticancer mechanisms remain largely inferred from studies of the individual ingredients rather than demonstrated for the complete formulation.
Primary mechanisms (ranked):
- PSA progression modulation: Reduced PSA rise in a six-month randomized clinical trial involving men with prostate cancer; the precise biological mechanism responsible for this clinical effect remains unconfirmed.
- Proliferation and survival signaling: Potential ↓ PI3K/AKT/mTOR, ↓ NF-κB, and modulation of MAPK signaling (model-dependent), based primarily on preclinical studies of constituent phytochemicals.
- Cell-cycle arrest and apoptosis: Potential ↓ cyclins and CDKs, ↑ p21/p27, ↑ caspase activation, and altered BCL-2/BAX balance (model-dependent).
- Inflammatory signaling: Potential ↓ NF-κB, COX-2, IL-6, TNF-α, and inflammatory transcriptional responses (context-dependent).
- Angiogenesis and invasion: Potential ↓ VEGF, HIF-1α, MMP-2/MMP-9, and metastatic signaling (model-dependent).
- Androgen receptor signaling: Possible ↓ androgen receptor activity and androgen-responsive transcription in prostate cancer models (context-dependent); direct suppression by Pomi-T in patients has not been demonstrated.
- Cellular redox regulation: Potential ↑ NRF2-dependent cytoprotective signaling and ↓ inflammatory oxidative stress in normal tissues; some constituent compounds induce ↑ ROS and mitochondrial apoptosis in cancer models at higher experimental concentrations.
- Epigenetic and metabolic modulation: Possible HDAC-related effects, altered glycolysis, and metabolic stress responses (model-dependent); clinical relevance of the combined formulation is uncertain.
Bioavailability / PK relevance: Pomi-T contains several phytochemical classes with different absorption and metabolism profiles. Green tea catechins have limited and variable systemic bioavailability. Curcumin undergoes extensive intestinal and hepatic metabolism, producing low unconjugated plasma concentrations after ordinary oral dosing. Pomegranate ellagitannins are extensively transformed by gut microbiota into urolithins, with substantial interindividual variability. Broccoli-derived glucosinolate conversion to active isothiocyanates depends on processing, myrosinase activity, and intestinal microbiota. Whole-food ingredient mass must not be equated with the mass of purified active phytochemicals.
In-vitro vs systemic exposure relevance: Many mechanistic cancer studies of EGCG, curcumin, sulforaphane, and ellagic acid use micromolar concentrations substantially exceeding typical concentrations of unconjugated compounds achievable from oral Pomi-T. The observed clinical PSA effect therefore cannot be attributed confidently to direct cytotoxic concentrations in prostate tissue. Metabolite activity, repeated low-level exposure, and indirect biological effects may contribute, but remain unconfirmed for this formulation.
Clinical evidence status: RCT evidence for PSA modulation in prostate cancer, supported by one principal six-month, double-blind, placebo-controlled trial involving 199 evaluable men. Median PSA increase was 14.7% with Pomi-T versus 78.5% with placebo (P=0.0008). This represents an improvement in a biochemical surrogate endpoint, not demonstrated improvement in metastasis-free or overall survival. Evidence is insufficient to establish Pomi-T as an anticancer treatment or replacement for standard care. Its use is investigational or adjunctive.
Safety / interpretation: The six-month prostate cancer trial reported no significant overall increase in adverse events compared with placebo. Long-term safety and interactions with anticancer drugs are incompletely characterized. Green tea extracts can cause liver injury, particularly at high EGCG exposures, while turmeric products may cause gastrointestinal or hepatic adverse effects and interact with medications. Appropriate caution is warranted in patients receiving systemic cancer therapy, anticoagulants, or medications with narrow therapeutic indices.
Pomi-T Mechanisms in Cancer
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
Primary Effect |
Notes / Interpretation |
| 1 |
PSA Progression |
↓ PSA progression clinically |
Not established |
Reduced PSA rise |
Direct Pomi-T RCT evidence in prostate cancer. Median PSA rise 14.7% versus 78.5% with placebo over six months. PSA is a surrogate endpoint, not direct proof of reduced tumor growth. |
| 2 |
PI3K / AKT / mTOR |
↓ (model-dependent) |
↔ / context-dependent |
↓ Proliferation and survival signaling |
Mechanistic evidence from constituent phytochemicals. Direct pathway inhibition by the complete Pomi-T formulation has not been established. |
| 3 |
Apoptosis / Cell Cycle |
↑ Caspase activation; ↑ BAX/BCL-2 ratio; ↓ cyclins |
Generally less affected (model-dependent) |
↑ Apoptosis; ↓ proliferation |
Primarily constituent-level cell culture and animal evidence. Concentration and tumor type influence the response. |
| 4 |
NF-κB / COX-2 / Inflammation |
↓ NF-κB, COX-2, IL-6 (context-dependent) |
↓ Inflammatory activation (context-dependent) |
Anti-inflammatory modulation |
Relevant to pomegranate, turmeric, green tea, and broccoli bioactives. Human Pomi-T trial did not demonstrate significant reduction in circulating CRP. |
| 5 |
Androgen Receptor Signaling |
↓ AR signaling (model-dependent) |
Not established |
Potential ↓ androgen-responsive growth |
Prostate cancer relevance inferred from individual ingredients. No demonstrated clinical reduction in androgen receptor activity or testosterone by Pomi-T. |
| 6 |
Angiogenesis / VEGF / HIF-1α |
↓ VEGF, HIF-1α (model-dependent) |
↔ / context-dependent |
↓ Angiogenic signaling |
Preclinical ingredient-level evidence. No validated antiangiogenic clinical outcome for Pomi-T. |
| 7 |
MMPs / Invasion / EMT |
↓ MMP-2, MMP-9; ↓ EMT signaling (model-dependent) |
Not established |
Potential ↓ invasion and migration |
Evidence from selected component models. Reduced metastatic progression has not been demonstrated clinically for the combined formulation. |
| 8 |
NRF2 / KEAP1 / Phase II Enzymes |
↔ / ↑ NRF2 (context-dependent) |
↑ NRF2, NQO1, HO-1, GSH-related defenses |
Adaptive antioxidant and electrophile-defense responses |
Particularly associated with broccoli-derived isothiocyanates. NRF2 activation can also support survival in NRF2-dependent tumors; anticancer benefit cannot be assumed. |
| 9 |
ROS / Mitochondrial Stress |
↑ ROS and mitochondrial apoptosis (high concentration only); ↔ / ↓ in other models |
↓ Oxidative stress (context-dependent) |
Redox-dependent signaling |
Bidirectional effects occur with constituent compounds. ROS-mediated cytotoxicity at experimental concentrations should not be extrapolated to standard oral Pomi-T dosing. |
| 10 |
Glycolysis / Metabolic Signaling |
↓ Glycolytic signaling (model-dependent) |
↔ / context-dependent |
Potential metabolic growth suppression |
Secondary mechanistic hypothesis from ingredient-level literature. No direct clinical demonstration of Pomi-T-mediated glycolysis inhibition. |
| 11 |
Epigenetic Regulation |
HDAC and DNA methylation modulation (model-dependent) |
Context-dependent |
Altered gene expression |
Reported for constituent phytochemicals in preclinical systems. Clinical exposure and contribution to the formulation's PSA response are uncertain. |
| 12 |
Chemosensitization / Radiosensitization |
Potential ↑ treatment sensitivity (model-dependent) |
Normal tissue effects uncertain |
Possible adjunctive interactions |
Based on individual phytochemical studies. No adequate evidence establishes improved treatment outcomes or safety when Pomi-T is combined with chemotherapy or radiotherapy. |
| 13 |
Clinical Translation Constraint |
Heterogeneous tumors; variable phytochemical exposure |
Variable metabolism and tolerability |
Limits mechanistic extrapolation |
Low unconjugated systemic concentrations, microbial metabolism, unspecified active-compound standardization, single short-duration prostate cancer RCT, and lack of validated metastasis or survival outcomes. |
Pomi-T Ingredient Composition
| Ingredient |
Original RCT Daily Dose |
Current Daily Dose |
Principal Bioactives |
| Pomegranate whole fruit |
300 mg |
300 mg |
Ellagitannins, ellagic acid, urolithin precursors |
| Broccoli powder |
300 mg |
300 mg |
Glucoraphanin, sulforaphane precursors, other glucosinolates |
| Turmeric root powder |
300 mg |
300 mg |
Curcumin, demethoxycurcumin, bisdemethoxycurcumin |
| Green tea extract 5:1 |
60 mg |
60 mg |
EGCG, other catechins |
| Total ingredient mass |
960 mg |
960 mg |
Botanical mass, not purified active-compound mass |
| Administration |
3 tablets daily |
2 capsules daily |
Six months in original RCT |
|